This
research
assesses
whether
participants’
responses
align
with
the
literature
concerning
cannabis
use
on
educational
attainment
and
employment
outcomes.
Mainly,
in
adolescence
is
associated
lower
attainment,
general
may
lead
to
poor
outcomes,
as
described
literature.
Participants
were
medical
dispensary
patients
a
California
card
residing
11
counties
or
near
San
Francisco
Bay
Area.
Data
collected
via
an
internet
survey
from
October
December
2017
32
dispensaries.
Medical
users
reported
having
bachelor’s
degrees
at
double
current
national
average.
The
majority
working
positions
without
random
drug
screening.
Company
screening
policies
affected
participants'
job
opportunities
upward
mobility.
Many
throughout
day,
especially
jobs
related
industry
among
those
high
personal
disclosure
work
individuals.
Most
participants
used
tetrahydrocannabinol
(THC)
cannabidiol
(CBD)
approximate
2:1
ratio.
Cannabis
was
for
pain,
anxiety,
insomnia,
depression.
One
limitation
that
this
study
lacks
more
diverse
sampling
of
individuals
who
do
not
obtain
sample
held
college
degrees,
gainfully
employed,
experiencing
little
no
stigmatization
use.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(8), P. 4176 - 4176
Published: April 10, 2024
Multiple
sclerosis
(MS)
is
an
autoimmune,
inflammatory,
and
neurodegenerative
disease
of
the
central
nervous
system
for
which
there
no
cure,
making
it
necessary
to
search
new
treatments.
The
endocannabinoid
(ECS)
plays
a
very
important
neuromodulatory
role
in
CNS.
In
recent
years,
formation
heteromers
containing
cannabinoid
receptors
their
up/downregulation
some
diseases
have
been
demonstrated.
Despite
beneficial
effects
shown
by
phytocannabinoids
MS,
ECS
its
pathophysiology
unknown.
main
objective
this
work
was
identify
cell
surface
proteins
receptive
cannabinoids,
namely
GPR55,
CB1
CB2
receptors,
brain
samples
from
control
subjects
MS
patients,
as
well
determining
cellular
localization,
using
Situ
Proximity
Ligation
Assays
immunohistochemical
techniques.
For
first
time,
CB1R-GPR55
CB2R-GPR55
are
identified
prefrontal
cortex
human
brain,
more
grey
than
white
matter.
Remarkably,
number
complexes
found
be
increased
patient
samples.
results
obtained
open
promising
avenue
research
on
use
these
receptor
potential
therapeutic
targets
disease.
Journal of Cannabis Research,
Journal Year:
2025,
Volume and Issue:
7(1)
Published: Feb. 27, 2025
Abstract
Background
Cannabis
sativa
L.
with
a
rich
history
of
traditional
medicinal
use,
has
garnered
significant
attention
in
contemporary
research
for
its
potential
therapeutic
applications
various
human
diseases,
including
pain,
inflammation,
cancer,
and
osteoarthritis.
However,
the
specific
molecular
targets
mechanisms
underlying
synergistic
effects
diverse
phytochemical
constituents
remain
elusive.
Understanding
these
is
crucial
developing
targeted,
effective
cannabis-based
therapies.
Methods
To
investigate
pathways
involved
cannabis
compounds,
we
utilized
DRIFT,
deep
learning
model
that
leverages
attention-based
neural
networks
to
predict
compound-target
interactions.
We
considered
both
whole
plant
extracts
plant-based
formulations.
Predicted
were
then
mapped
Reactome
pathway
database
identify
biological
processes
affected.
facilitate
prediction
associated
any
user-specified
formulation,
developed
CANDI
(Cannabis-derived
compound
Analysis
Network
Discovery
Interface),
web-based
server.
This
platform
offers
user-friendly
interface
researchers
drug
developers
explore
compounds.
Results
Our
analysis
using
DRIFT
successfully
identified
numerous
many
which
are
relevant
other
diseases.
The
server
enables
affected
providing
valuable
insights
targeted
Conclusions
By
combining
computational
approaches
knowledge
have
server,
tool
allows
us
harness
compounds
treatment
disorders.
bridging
pharmaceutical
development
medicine,
propose
novel
approach
botanical-based
modalities.
Recent
studies
have
shown
that
the
endogenous
cannabinoid
system
(ECS)
of
brain
is
essentially
involved
in
pathogenesis
Parkinson's
disease
(PD),
influencing
its
symptoms
by
regulating
level
cannabinoids
and
altering
activation
receptors
(CBR).
Therefore,
modulation
ECS
with
new
drugs
developed
for
this
purpose
may
prove
to
be
a
promising
strategy
treatment
PD.
However,
fine
regulation
quite
challenge
due
functional
diversity
CBR
basal
ganglia.
Our
review
analyses
effects
modulators
on
experimental
PD
models
patients
PD,
as
well
presents
outlooks
development
motor
non-motor
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(15), P. 8520 - 8520
Published: Aug. 5, 2024
The
endogenous
cannabinoid
system
(ECS)
of
the
brain
plays
an
important
role
in
molecular
pathogenesis
Parkinson’s
disease
(PD).
It
is
involved
formation
numerous
clinical
manifestations
by
regulating
level
cannabinoids
and
changing
activation
receptors
(CBRs).
Therefore,
ECS
modulation
with
new
drugs
specifically
designed
for
this
purpose
may
be
a
promising
strategy
treatment
PD.
However,
fine
regulation
quite
complex
task
due
to
functional
diversity
CBRs
basal
ganglia
other
parts
central
nervous
system.
In
review,
effects
modulators
various
experimental
models
PD
vivo
vitro,
as
well
patients
PD,
are
analyzed.
Prospects
development
motor
non-motor
symptoms
presented.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 9, 2024
Abstract
Background:
Cannabis
sativa
with
a
rich
history
of
traditional
medicinal
use,
has
garnered
significant
attention
in
contemporary
research
for
its
potential
therapeutic
applications
various
human
diseases,
including
pain,
inflammation,
cancer,
and
osteoarthritis.
However,
the
specific
molecular
targets
mechanisms
underlying
synergistic
effects
diverse
phytochemical
constituents
remain
elusive.
Understanding
these
is
crucial
developing
targeted,
effective
cannabis-based
therapies.
Methods:
To
investigate
pathways
involved
cannabis
compounds,
we
utilized
DRIFT,
deep
learning
model
that
leverages
attention-based
neural
networks
to
predict
compound-target
interactions.
We
considered
both
whole
plant
extracts
plant-based
formulations.
Predicted
were
then
mapped
Reactome
pathway
database
identify
biological
processes
affected.
facilitate
prediction
associated
any
user-specified
formulation,
developed
CANDI
(Cannabis-derived
compound
Analysis
Network
Discovery
Interface),
web-based
server.
This
platform
offers
user-friendly
interface
researchers
drug
developers
explore
compounds.
Results:
Our
analysis
using
DRIFT
successfully
identified
numerous
many
which
are
relevant
other
diseases.
The
server
enables
affected
providing
valuable
insights
targeted
Conclusions:
By
combining
computational
approaches
knowledge
have
server,
tool
allows
us
harness
compounds
treatment
disorders.
bridging
pharmaceutical
development
medicine,
propose
novel
approach
botanical-based
modalities.
Rare Disease and Orphan Drugs Journal,
Journal Year:
2024,
Volume and Issue:
3(3)
Published: Aug. 23, 2024
Aims
:
Using
an
investigator-designed
survey
tool
to
confirm
that
adult
patients
with
type
1
Gaucher
disease
(GD1)
often
self-prescribe
cannabis
products
try
alleviate
symptoms
such
as
lingering
fatigue,
chronic
bone
and
joint
pain,
loss
of
energy,
anxiety,
depression
persist
despite
enzyme
replacement
therapy
(ERT)
or
substrate
restriction
(SRT).
Additionally,
explore
whether
patient
reports
symptom
relief
adverse
side
effects
relate
frequency
duration
use.
Methods
We
conducted
anonymous,
cross-sectional
questionnaire
study
elicit
GD1
patient-reported
experiences
used
they
attributed
their
underlying
disease.
Eligible
participants
included
individuals
aged
≥
18
years,
regardless
sex,
gender,
country
residence,
ethnicity,
state
health
treatment
status.
The
questions
basic
socio-demography
(n
=
9),
GD
diagnosis
pre-treatment
signs
16),
information
current
12),
concurrent
manifestations
Parkinson’s
6),
details
use
24),
perceived
effect
on
13),
interest
in
participating
future
studies
2).
Results:
159
adults
(81.5%
US)
responded
advertisements
online
sites
informational
posts
advocacy
group
newsletters.
most
frequent
were
fatigue
(83.8%),
pain
(79.7%),
bleeding
problems
(73.0%).
Hemostasis
substantially
improved,
but
achiness,
anxiety
persisted.
Sixty-two
respondents
(39%)
reported
very
heterogeneous
There
was
a
positive
association
between
the
severity
persistent
likelihood
Cannabis
users
improvements
muscle
(84.3%),
(82.4%),
(70.6%),
general
achiness
(66.7%).
However,
moderate
extreme
manifestations,
breathing
problems,
memory
loss,
episodic
dyscoordination
more
prevalent
among
inhaled
than
non-users.
Conclusion:
Our
results
justify
further
investigations
determine
efficacy
safety
specifically
for
patients.
Although
randomized
controlled
trials
would
be
optimal,
well-designed
observational
registry
may
practical
approach.
some
reluctant
talk
openly
doctors
about
cannabis,
should
routinely
queried
by
primary
care
physicians
specialists
who,
turn,
must
able
provide
informed
guidance
safety,
dosage,
potential
interactions
other
medications
is
using.
Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: July 24, 2023
There
is
a
need
for
more
research
examining
the
use
of
cannabis,
tetrahydrocannabinol
(THC),
and
cannabidiol
(CBD)
products
in
people
with
Parkinson's
disease
(PD),
especially
given
recent
increase
these
products.Given
over-the-counter
CBD
as
well
prescription
medical
cannabis
by
treating
physicians,
utilization
method,
effects
on
motor
non-motor
symptoms,
side
effects,
attitude
toward
were
examined
naturalistic
sample
patients
PD.A
total
15
individuals
PD,
eight
whom
prescribed
CBD/THC
treatment
seven
who
not
taking
any
product,
assessed
cross-sectionally.
Participants
completed
structured
neuropsychological
testing,
assessment,
questionnaires
regarding
mood,
subjective
cognition,
symptom
levels.
T-tests
quantitative
measures
descriptive
data
described.
Due
to
small
size,
Shapiro-Wilk
tests
normality
utilized
Mann-Whitney
U
analyses
when
appropriate.We
found
wide
range
methods
variability
perceived
benefits
untoward
even
our
sample.
Individuals
PD
product
had
lower
global
cognition
scores
Montreal
Cognitive
Assessment
(MoCA)
but
no
detectable
differences
among
specific
measures.
They
also
symptoms
Qualitatively,
some
participants
reported
improved
pain
levels,
sleep,
reductions
anxiety.
A
few
negative
endorsed,
including
sleepiness,
concentration
difficulties,
forgetfulness.CBD/THC
varied.
In
sample,
MoCA
scores,
descriptively
improvements
anxiety,
pain,
sleepiness
cognitive
difficulty.
Future
studies
should
focus
clinical
trials
standardized
use.
Journal of Medicinal Chemistry,
Journal Year:
2023,
Volume and Issue:
66(18), P. 12858 - 12876
Published: Sept. 14, 2023
From
our
NETSseq-derived
human
brain
transcriptomics
data,
we
identified
GPR55
as
a
potential
molecular
target
for
the
treatment
of
motor
symptoms
in
patients
with
Parkinson's
disease.
high-throughput
screen,
and
optimized
agonists
nanomolar
potency
against
both
rat
GPR55.
We
discovered
compounds
either
strong
or
limited
β-arrestin
signaling
receptor
desensitization,
indicating
biased
signaling.
A
compound
that
showed
minimal
desensitization
demonstrated
reduction
firing
frequency
medium
spiny
neurons
cultured
from
striatum
but
did
not
reverse
deficits
hypolocomotion
model.
Further
profiling
several
desensitizing
non-desensitizing
lead
they
are
selective
over
related
cannabinoid
receptors
CB1
CB2
unbound
concentrations
well
above
respective
EC50
can
be
readily
achieved
following
oral
administration.
The
novel
brain-penetrant
disclosed
used
to
probe
role
this
brain.
